CD8

[Nature Communications] Scientists showed CD1b-mycolipid tetramers revealed a hierarchy in which circulating T cells expressing CD4 or CD8 co-receptor stain with a higher tetramer mean fluorescence intensity than CD4-CD8- T cells.

[AIDS] Researchers studied CD4/CD8 over time to determine whether it predicted risk for select comorbidities and mortality among aging people with HIV with viral suppression.

[Fate Therapeutics, Inc.] Fate Therapeutics, Inc. announced that the US FDA has cleared the company’s Investigational New Drug application for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor NK cell product candidate.

[Science Immunology] Researchers developed a tumor-conditional interleukin-12 (pro-IL-12), which masked IL-12 with selective extracellular receptor–binding domains of the IL-12 receptor while preferentially and persistently activating tumor-infiltrating lymphocytes after being unmasked by matrix metalloproteinases expressed by tumors.

[Cellular & Molecular Immunology] The in vivo recovery of cytomegalovirus (CMV)-specific immunity after CMV-cytotoxic T lymphocytes (CTL) infusion was comparable in two groups. A detailed analysis of the source of recovered CMV-CTLs showed the proliferation and expansion of graft-derived endogenous CMV-CTLs in both groups.

[Nature Communications] Investigators found that GATA4 promoted non-cell autonomous tumor suppression in multiple model systems. Mechanistically, they showed that Gata4-dependent tumor suppression required cytotoxic CD8 T cells and partially required the secreted chemokine CCL2.